India Glycols Q4 FY26 Earnings Call Transcript Released
India Glycols reported FY26 revenues of ₹9,827 Cr (up 8.7%) and EBITDA of ₹654 Cr (up 24.5%). Q4 FY26 saw net revenues of ₹976 Cr (up 13.1%) and EBITDA of ₹167 Cr (up 13.3%). The company prepaid ₹804 Cr debt, saving ₹20 Cr in interest. Management discussed growth drivers in Bio-Fuels and Potable Spirits.
The announcement provides a detailed financial performance update for the full year and the latest quarter, including key financial metrics and segment-wise performance. This information is material for investors' decision-making.
The company reported strong year-on-year growth in revenues, EBITDA, and PAT for both the full year and the fourth quarter. The management expressed optimism about future performance and highlighted strategic initiatives driving growth.
India Glycols Limited has released the transcript of its Q4 and Full Year FY26 Earnings Conference Call, which was held on May 18, 2026. The call featured management including CEO Mr. Rupark Sarswat and CFO Mr. Anand Singhal, along with representatives from InCred Equities.
During the call, the company reported strong financial performance for FY26, with gross revenues of ₹9,827 crores (up 8.7%) and net revenues of ₹4,211 crores (up 11.8%). EBITDA stood at ₹654 crores, marking a 24.5% increase, with EBITDA margins improving to 15.5%. Profit After Tax (PAT) was ₹293 crores, up 26.8%.
The Q4 FY26 performance also showed robust growth, with net revenues of ₹976 crores (up 13.1%) and EBITDA of ₹167 crores (up 13.3%), leading to an EBITDA margin of 17.1%. The company highlighted that its other income, largely from a Joint Venture, brings the effective EBITDA margin closer to 20.8%.
Key business segments contributing to the growth included Potable Spirits and Bio-Fuels, with Chemicals also showing margin improvements despite a dip in sales. The company noted the positive impact of India reaching 20% blending for Bio-Fuels and strategies for premiumization in the Potable Spirits segment.
Management discussed the mixed impact of geopolitical events on raw material prices and exports. They also detailed segment-wise performance, with Bio-Fuels showing significant growth and Chemicals focusing on higher value-added products. Ennature Biopharma's performance was stable, with efforts to strengthen its portfolio.
Financial highlights included the prepayment of approximately ₹804 crores in debt, funded through an equity issue and cash flow, resulting in ₹20 crores of interest cost savings. The company also clarified that dividend income from its JV, Clariant, amounting to ₹38.38 crores, was adjusted against investments as per accounting standards.
A plant shutdown for catalyst changeover from March 17th to April 2nd was mentioned, which impacted the production of ethylene oxide for the JV and certain other products like glycol ethers and specialty surfactants. The company expects improved profitability and top-line growth in the Chemicals business going forward, with a cautious optimism for the short term and bullish outlook based on ongoing projects.
What to do with a filing like this
India Glycols Limited filed this with the NSE as a statutory disclosure, categorised under concall scheduled. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by India Glycols Limited. Read the original for the full detail.